Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 dopamine receptors. Under normal conditions, prolactin secretion from the anterior pituitary is mainly inhibited by dopamine released from hypothalamic tuberoinfundibular neurons.
Cabergoline produces a direct inhibitory effect on prolactin secretion from pituitary lactotroph cells. It has relatively low affinity for dopamine D1, alpha-1 and alpha-2 adrenergic, and 5-HT1 and 5-HT2 serotonin receptors.
Cabolin belongs to a group of medicines called dopamine receptor agonists. It works primarily by stimulating dopamine D2 receptors in the pituitary gland, thereby reducing the secretion of prolactin.
By lowering elevated prolactin levels, cabergoline can help restore hormonal balance and improve symptoms associated with hyperprolactinemia.
১০০% অরিজিনাল পণ্যের নিশ্চয়তা
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Cabolin contains cabergoline, a dopamine receptor agonist that lowers the production of prolactin, a hormone released by the pituitary gland.
It is used to:
The usual starting dose is 0.25 mg twice weekly. Depending on the patient's serum prolactin level and response to treatment, the dose may be increased by 0.25 mg twice weekly.
Dose increases should generally be made no more frequently than every 4 weeks to allow adequate assessment of response and tolerability. The dose should be individualized according to the lowest dose that provides an adequate response.
In patients who maintain normal prolactin levels for an extended period, the physician may consider discontinuing treatment with periodic monitoring to determine whether treatment needs to be restarted.
A single 1 mg dose is generally taken on the first day after delivery when suppression of lactation is indicated.
A total dose of 0.5 mg, divided into two doses of 0.25 mg taken 12 hours apart for one day, may be used when medically appropriate.
Treatment is generally initiated with a low dose, such as 0.5 mg per week, divided into one or two doses. The dose may be gradually adjusted according to serum prolactin levels and clinical response.
The maximum dose may be increased under specialist supervision when necessary.
Do not change the dose or frequency without medical advice.
Supportive treatment and monitoring of blood pressure may be required. Seek immediate medical attention if an overdose is suspected.
Women who are pregnant, planning pregnancy, or who may become pregnant should discuss cabergoline treatment with their doctor.
Pregnancy should generally be excluded before treatment is initiated when cabergoline is being used for hyperprolactinemia. If pregnancy occurs during treatment, the physician should be informed so that the need for continued treatment can be reassessed.
Cabergoline suppresses prolactin secretion and therefore reduces or prevents breast milk production. It should not be used by women who intend to establish or continue breastfeeding unless specifically prescribed for another medical reason.
Store in a cool, dry place protected from light. Keep the medicine out of reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.